% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Berger:136660,
      author       = {A. K. Berger and S. Lücke$^*$ and U. Abel$^*$ and G. M.
                      Haag and C. Grüllich and A. Stange and M. Dietrich and L.
                      Apostolidis and A. Freitag$^*$ and C. Trierweiler$^*$ and C.
                      von Gall and J. Ose and F. Giesel and T. F. Weber and F.
                      Lordick and U. Haberkorn and D. Jäger},
      title        = {{E}arly metabolic response in sequential {FDG}-{PET}/{CT}
                      under cetuximab is a predictive marker for clinical response
                      in first-line metastatic colorectal cancer patients: results
                      of the phase {II} {REMOTUX} trial.},
      journal      = {British journal of cancer},
      volume       = {119},
      number       = {2},
      issn         = {1532-1827},
      address      = {Edinburgh},
      publisher    = {Nature Publ. Group},
      reportid     = {DKFZ-2018-01129},
      pages        = {170 - 175},
      year         = {2018},
      abstract     = {To assess the predictive value of early metabolic response
                      (ΔSUV) after short-term treatment with first-line cetuximab
                      in patients (pts) with RAS-wt metastatic colorectal cancer
                      (mCRC).In this prospective phase II study, RAS-wt mCRC pts
                      received a single-agent cetuximab run-in therapy of 2 weeks.
                      ΔSUV was assessed with FDG-PET/CT on days 0 and 14. Early
                      clinical response (ECR) was evaluated with CT on day 56
                      after treatment with FOLFIRI-cetuximab. Primary endpoint was
                      the predictive significance of ΔSUV for ECR. Secondary
                      endpoints were PFS (progression free survival), OS and the
                      influence of ΔSUV on survival.Forty pts were enroled and 33
                      pts were evaluable for the primary endpoint. The CT response
                      rate was $57.6\%.$ For responders, ΔSUV was significantly
                      higher (p = 0.0092). A significant association of ΔSUV
                      with ECR was found (p = 0.02). Median PFS was 11.7
                      months and median OS was 33.5 months with a 1-year survival
                      rate of $87.9\%.$ ΔSUV was found to significantly impact
                      the hazard for OS (p = 0.045).We demonstrate that
                      cetuximab induces metabolic responses in mCRC pts. The study
                      endpoint was met with the ΔSUV discriminating between
                      responders and non-responders. However, these data should be
                      validated in larger patient cohorts.},
      cin          = {G040},
      ddc          = {610},
      cid          = {I:(DE-He78)G040-20160331},
      pnm          = {319H - Addenda (POF3-319H)},
      pid          = {G:(DE-HGF)POF3-319H},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29961759},
      doi          = {10.1038/s41416-018-0152-4},
      url          = {https://inrepo02.dkfz.de/record/136660},
}